Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Mastering KAM excellence: achieving meaningful growth from top accounts

By Aaron Bean

- PMLiVE

Novo Nordisk gains rights to United Laboratories’ triple receptor agonist in deal worth $2bn

UBT251 is in early-stage clinical development for type 2 diabetes, obesity and other diseases

- PMLiVE

Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

Approximately half of C3G patients progress to kidney failure within ten years of diagnosis

- PMLiVE

GSK to explore link between Shingrix and dementia risk in new UK research collaboration

More than 55 million people worldwide are currently living with the neurodegenerative disease

- PMLiVE

Breaking boundaries in medical affairs: how measurable outcomes redefine success

By Caroline Phillips

- PMLiVE

Live Q&A: Beyond NHS England – Restructuring and its implications for Pharma and Medtech

What does the abolition of NHS England mean for your market access and NHS Engagement strategy? How will the changes at national and integrated care board (ICB) level impact launch...

Petauri Evidence

- PMLiVE

Medscape at ACC 2025: From Taking the Pulse to Getting to the Heart of It

The Medscape team is back in Chicago for the much-anticipated ACC 2025 conference,  March 29-31, bringing an array of engaging educational booth highlights, interactive symposia, scientific posters, and more for...

Medscape Education

- PMLiVE

Johnson & Johnson to invest more than $55bn in US over next four years

The commitment marks a 25% increase to the company's US investments in the past four years

- PMLiVE

AstraZeneca announces $2.5bn investment in China to boost R&D capabilities

The funds will go towards a new global research and development centre in Beijing’s BioPark

- PMLiVE

Alnylam’s Amvuttra granted FDA approval for rare heart disease ATTR-CM

Approximately 150,000 people in the US are affected by transthyretin amyloid cardiomyopathy

- PMLiVE

From zero to hero: is zero-party data your new best friend for omnichannel HCP engagement?

By Rupert Watts

- PMLiVE

Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn

The companies will aim to discover new antibody-based therapeutics for cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links